New hope for essential thrombocythemia patients: experimental drug targets overactive platelet production
NCT ID NCT04081220
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests an experimental drug called IMG-7289 in 9 adults with essential thrombocythemia, a rare blood disorder causing too many platelets. The drug aims to lower platelet counts and ease symptoms. Participants take a daily pill, with doses adjusted individually. The main goal is to see how many achieve complete remission by 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IMG-7289 (LSD1 inhibitor)
- What this could lead to
- If successful, this could offer a new treatment option for people with essential thrombocythemia who cannot take or do not respond to standard therapy.
- What could go wrong
- This is a very small, early-phase trial with only 9 participants, so results may not apply to a larger population. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTHEMIA ESSENTIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mays Cancer Center
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.